The FDA will decide on July 6 whether to grant full approval to the new Alzheimer's treatment Leqembi, Japanese drugmaker Eisai and its U.S. partner Biogen said.

A report by two House committees found that the Food and Drug Administration's controversial approval of the Alzheimer's drug Aduhelm was "rife with irregularities."

Biopharmaceutical company Biogen has picked a new CEO, former Sanofi CEO Christopher Viehbacher, amid fallout from its failed Alzheimer's drug launch.

Department of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.

Biogen said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm.

Apple is working on features designed to detect depression, anxiety, autism and the cognitive decline that can develop into Alzheimer’s and other kinds of dementia, according to a Tuesday report in the Wall Street Journal.

President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.

An expert panel unanimously voted that Biogen’s controversial Alzheimer’s drug does not provide more benefit to patients than supportive care.

The Food and Drug Administration’s acting commissioner, Janet Woodcock, is taking the highly unusual step of asking for a federal investigation of doctors within her own agency who met with the makers of an Alzheimer’s drug prior to the medicine’s FDA approval.

U.S. health regulators on Thursday approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer’s drug.